R&D strategy

With a deeper understanding in oncology and autoimmune disease biology many tentalizing drug targets have emerged but many of them are not amenable to inhibition by traditional small molecules and are deemed undruggable. These include transcription factors, targets that have non-enzymatic scaffolding functions or have no deep pockets suitable for tight binding of small molecule drugs. Some disease drivers have multiple downstream signaling branches or multiple disease-relevant mutations that traditional small molecules are not able to cover adequately.  In such cases, degradation of the disease driver by a PROTAC provides a superior approach to completely block the disease driver.

At Polymed, we select targets where the PROTAC-based approach is expected to have the most robust therapeutic impact and leverage our unique linker technology to rapidly advance PROTAC molecules into the clinic.